FDA Approves Noxafil Delayed-Release Tablets
Noxafil is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients >13 years old who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia (low white blood cell counts) from chemotherapy.
Posaconazole is an antifungal that blocks the synthesis of ergosterol through the inhibition of lanosterol 14α-demethylase, a CYP450 dependent enzyme that is responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane.
This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane.
Noxafil delayed-release tablets will be available in a 100mg strength in 60-count bottles. Noxafil oral suspension is currently available in a 40mg/mL strength in 4 ounce bottles.
For more information call (800) 672-6372 or visit Noxafil.com.